Impact of host genomic variation on clinical outcomes in HIV patients
Leading partner organisation: REGION HOVEDSTADEN/Centre of Excellence for Health, Immunity and Infections (CHIP) (Denmark)
The HIV epidemiology and virology related tasks will be complemented by clinically oriented activities based on host genetics.
CARE aims at performing an assessment of the treatment-limiting toxicity for existing antiretroviral drugs through:
Establishment of a pilot cohort for the study of the impact of host genetics on the risk of development of AIDS and serious non-AIDS events, and adverse drug reactions in HIV-positive patients in Eastern Europe (Russia, Georgia and Ukraine), based on the single nucleotide polymorphism study performed at CHIP/RegionH
Preliminary validation of the data by comparing it to an existing extensive cohort in relation to most common treatment regimens